Multiple Myeloma

A review of clinical trial data on bispecific antibodies in multiple myeloma and clinical insights on how these medications have changed clinical practice.

Dive into a compelling case study showcasing the effective use of talquetamab therapy in the management of relapsed multiple myeloma, discussing responses, side effects, and treatment outcomes.

The panel reviews the profiles of 2 patients with multiple myeloma and provides their initial thoughts regarding treatment approaches.

Faiz Answer, MD, FACP, reviews data from the REMIX study on the real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma.

Experts in the field of multiple myeloma discuss data from a retrospective study on patients with multiple myeloma.

Dr Luciano Costa discusses treatment options for patients with multiple myeloma with early vs late relapse, noting that those with early aggressive relapse have limited options and often rapidly exhaust available therapies, emphasizing the need for newer agents like bispecific antibodies.

Binod Dhakal, MD, presents the case of a young man with aggressive relapsed multiple myeloma to the panel for discussion.

Join moderator Sagar Lonial, MD, FACP, and a panel of experts as they discuss recent updates in the management of relapsed and refractory multiple myeloma, exploring impact on clinical practice.

Expert perspectives on treatment decision-making in early-relapse multiple myeloma and the efficacy of CAR T-cell therapy.

A panel of oncologists give an overview of clinical trial data surrounding the management of early-relapse multiple myeloma.

Jeffrey A. Zonder, MD, reviews data on patient outcomes following biochemical or clinical progression in multiple myeloma.

The expert panel discusses the efficacy and durability of response of ciltacabtagene autoleucel in patients with multiple myeloma.

ISB 1342 has shown improved safety and efficacy for patients with relapsed/refractory multiple myeloma.

UT Southwestern and Mayo Clinic debated over current treatment options in chronic myeloid leukemia and multiple myeloma.

Jack Khouri, MD, discusses phase 3 results from the CARTITUDE-4 study investigating ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma.

Following a review of data from the ALLIANCE A061202 study, experts on multiple myeloma discuss treatment considerations for patients being treated with ixazomib, pomalidomide, and dexamethasone.

Fred Hutch and City of Hope "Face Off" regarding presentations focusing on multiple myeloma and chronic myeloid leukemia.

Concluding their comprehensive discussion on treating patients with multiple myeloma, the expert panel discusses unmet needs and looks to the future of treatment.

The panel presents the case of a 68-year-old man with multiple myeloma and offers their initial impressions.

Investigators discussed the potential link between secondary pure red cell aplasia and subcutaneous daratumumab/hyaluronidase formulation for multiple myeloma.

Andrew Kin, MD, reviews data on the addition of ixazomib to pomalidomide and dexamethasone in patients with multiple myeloma who progressed on lenalidomide in the first line.

A panel of experts on multiple myeloma from Karmanos Cancer Institute and Cleveland Clinic introduce themselves and prepare for a team-vs-team debate surrounding recent data in multiple myeloma.

Shared insights on the patient profile of a 75-year-old woman with multiple myeloma with confirmed lytic disease.

The expert panel presents the patient case of a 70-year-old man with multiple myeloma and discusses treatment decisions.

Panelists review the CARTITUDE-4 study results highlighting the efficacy of cilta-cel in lenalidomide-refractory multiple myeloma, addressing implementation challenges and patient preferences in varying relapse scenarios.

Experts from City of Hope close out their panel on multiple myeloma management by identifying unmet needs and sharing what excites them in the future evolution of the treatment landscape.

The panel shares some personal experiences with treating patients with multiple myeloma with a quadruplet therapy regimen.

An overview of the RedirecTT-1 study investigating teclistamab plus talquetamab in patients with relapsed/refractory multiple myeloma.

Continuing discussion on bispecific antibodies, attention turns to talquetamab and the MonumenTAL-1 clinical trial for patients with relapsed/refractory multiple myeloma.

Leading experts discuss the potential benefits and challenges of using ixazomib pomalidomide-dexamethasone as a treatment option for relapsed myeloma patients, considering factors like efficacy, overall survival, and patient demographics.